home

Novartis muscular drug fails in Phase III trials

Trendpharmafile2016-04-25 15:02 Read   114

A muscular drug developed by Novartis (NYSE: NVS), in partnership with MorphoSys (ETR: MOR), failed to meet its primary endpoint in a Phase IIb/III study, raising doubts over the future of BYM338 (bimagrumab) which was originally designated a “breakthrough” therapy by the US Food and Drug Administration.

New Novartis meds help relieve Gleevec generics pain

Trendfiercepharma2016-04-22 11:09 Read   98

It’s accentuate-the-positive time at Novartis. The Swiss drugmaker’s sales and earnings suffered in the first quarter, thanks to an early generic version of blockbuster leukemia drug Gleevec.

What Andy Grove and Michael Milken Have Taught Us About Prostate Cancer ARNI, MDVN

Trendthelifesciencesreport2016-04-22 10:46 Read   83

Solid tumors are typically managed with surgical resection, chemotherapy, radiation and biologics, but it's the secondary tumor mass, the metastasis, that kills patients. Dr. Stuart Holden of the UCLA Institute of Urologic Oncology understands the importance of targeting metastatic disease, which is driven by different genetic factors than the primary tumor from which it arose—a fact that oncologists are just now coming to grips with.

Common Class of Breast Cancer Drugs May Not Trigger 'Chemo Brain': Study

Trenddrugs2016-04-22 09:53 Read   90

THURSDAY April 21, 2016, 2016 -- Some breast cancer patients complain of a fogged mental condition often called "chemo brain," experienced after their therapy.

MedDay hails new progressive MS data as EMA filing beckons

Trendfiercebiotech2016-04-22 09:18 Read   90

French biotech MedDay has posted the full, follow-up data from two mid- to late-stage trials for its multiple sclerosis candidate, showing it has a long-term impact on reversing progression in the disease in a difficult-to-treat patient population.

MorphoSys AG : MorphoSys Provides Update on Results From Partner's Phase 2b/3 RESILIENT Study of Bimagrumab

TrendMorphoSys2016-04-22 09:13 Read   222

Bimagrumab Did Not Meet Its Primary Endpoint in Patients with sIBM

AbbVie and argenx to Collaborate on ARGX-115 Against Novel Immuno-Oncology Target

TrendAbbVie2016-04-22 09:06 Read   85

The Netherlands and GHENT, Belgium, April 21, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, and argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies to treat cancer and severe autoimmune diseases will collaborate to develop and commercialize ARGX-115.

Argos Lays Off 18 and Executive Resigns, But Phase 3 Still on Track

Trendxconomy2016-04-21 14:50 Read   104

Argos Therapeutics has already secured financing expected to carry the company far enough to report late-stage clinical trial results for its experimental kidney cancer treatment, but that hasn’t stopped the company from taking additional cost-cutting measures.

Dynavax Presents Pivotal Phase 3 Data Showing HEPLISAV-B(TM) Provides Significantly Higher Protection Against Hepatitis B Than Engerix-B(R)

Trenddynavax2016-04-21 14:08 Read   84

Data Presented at NFID's Annual Conference on Vaccine Research

First Presentation of Overall Survival Data for Opdivo® (nivolumab) Shows Significant Survival Benefit at One-Year Versus Investigator’s Choice in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Trendbms2016-04-21 14:01 Read   94

Bristol-Myers Squibb Company (NYSE: BMY) announced today the first presentation of data from CheckMate -141, a Phase 3 open-label, randomized trial, evaluating Opdivo in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) after platinum therapy compared to investigator’s choice of therapy (methotrexate, docetaxel, or cetuximab).

Duke scientists crystallize protein, unlocking new antibiotic development window

Trendfiercebiotech2016-04-21 09:50 Read   88

Cara Therapeutics, Inc. (CARA), today announced that it has received notice from the U.S. Food and Drug Administration (FDA) that it has removed the clinical hold on its adaptive Phase 3 trial of I.V. CR845 for postoperative pain.

Cara Therapeutics Announces Removal of FDA Clinical Hold on CLIN3001 Postoperative Pain Trial for I.V. CR845

TrendYAHOO2016-04-21 09:35 Read   103

Cara Therapeutics, Inc. (CARA) today announced that it has received notice from the U.S. Food and Drug Administration (FDA) that it has removed the clinical hold on its adaptive Phase 3 trial of I.V. CR845 for postoperative pain.